Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout
When used as part of a comprehensive weight loss program that includes dietary changes and regular physical activity, GLP-1 injections can support significant weight loss while improving long-term health outcomes
GLP-2 is administered via once-weekly subcutaneous injections, a simple and convenient method that integrates easily into your routine
The pill was also associated with lower markers of cardiovascular risk, including cholesterol and blood pressure
As First-Line Treatment Guidelines increasingly support GLP-1 agonists as first-line treatment alongside or instead of metformin: When to consider first-line GLP-1: Established cardiovascular disease High cardiovascular risk Significant obesity (BMI 35+) Strong desire for weight loss Insurance coverage available Traditional metformin-first approach: Lower cost without insurance Decades of safety data Effective for many patients Can add GLP-1 later if needed For many patients, starting with a GLP-1 medication rather than metformin provides superior comprehensive benefit
